SOME THROMBOCYTE FACTORS DEVELOPMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C

SOME THROMBOCYTE FACTORS DEVELOPMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C

Purpose: to examine the frequency of mutations W 515K and W 515L in the Mpl, the encoder receptors platelets to thrombopoietin and determine the degree of activity of enzymes of blood platelets - glycogen, alpha-naphthylhesterase(αANАE) and adenosine triphosphatase (ATPase). at patients with chronic...

Full description

Bibliographic Details
Main Authors:	N. Y. Pshenichnaya, G. V. Kuznetsova
Format:	Article
Language:	English
Published:	State Budget Educational Institute of Higher Professional Education, Rostov State Medical University, Ministry Health of Russian Federation 2013-03-01
Series:	Медицинский вестник Юга России
Subjects:	thrombocytopenia chronic hepatitis c platelet thrombopoietin receptors platelets enzyme activity
Online Access:	https://www.medicalherald.ru/jour/article/view/67

Similar Items

Recent advance of pathogenesis of TPO in thrombocytes and its clinical use in patients with chronic liver disease
by: PI Sainan, LI Liang, YANG Mo, CHEN Youpeng
Published: (2024-09-01)

Hepatitis C virus-associated thrombocytopenia is not related to serum thrombopoietin levels
by: Afifi Ola, et al.
Published: (2007-01-01)

Baseline thrombopoietin level is associated with platelet count improvement in thrombocytopenic chronic hepatitis C patients after successful direct-acting antiviral agent therapy
by: Yen-Chun Chen, et al.
Published: (2021-01-01)

Lusutrombopag is effective and safe in patients with chronic liver disease and severe thrombocytopenia: a multicenter retrospective study
by: Hiroaki Nomoto, et al.
Published: (2020-12-01)

Serum thrombopoietin and cMpl expression in thrombocytopenia of different etiologies
by: Fabrizio Vianello, et al.
Published: (2014-03-01)

Recombinant human thrombopoietin in critically ill patients with sepsis-associated thrombocytopenia: A clinical study
by: Yu Liu, et al.
Published: (2020-09-01)

A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia
by: Heng Mei, et al.
Published: (2021-02-01)

Trends in the prevalence of thrombocytopenia among individuals iInfected with hepatitis C Virus in the United States, 1999-2008
by: Kauf Teresa L, et al.
Published: (2012-03-01)

Chronic liver disease, thrombocytopenia and procedural bleeding risk; are novel thrombopoietin mimetics the solution?
by: Sven R. Olson, et al.
Published: (2019-08-01)

Romiplostim in chemotherapy‐induced thrombocytopenia: A review of the literature
by: Gerald A. Soff, et al.
Published: (2024-08-01)

Thrombopoietin receptor agonist antibody for treating chemotherapy-induced thrombocytopenia
by: Jiwon Shin, et al.
Published: (2023-05-01)

Use of thrombopoietin receptor agonists in childhood immune thrombocytopenia
by: Angelica Maria Garzon, et al.
Published: (2015-08-01)

Successful treatment with eltrombopag in avoiding splenectomy for patients with chronic refractory immune thrombocytopenia
by: Alhossain A. Khalafallah, et al.
Published: (2012-01-01)

PATHOBIOLOGY AND TREATMENT OF HEPATITIS VIRUS-RELATED THROMBOCYTOPENIA
by: Roberto Stasi, et al.
Published: (2009-11-01)

Thrombopoietin receptor agonist (TPO-RA) treatment raises platelet counts and reduces anti-platelet antibody levels in mice with immune thrombocytopenia (ITP)
by: Rick Kapur, et al.
Published: (2020-04-01)

Spotlight on romiplostim in the treatment of children with chronic immune thrombocytopenia: design, development, and potential place in therapy
by: Buchbinder D, et al.
Published: (2017-03-01)

The pathophysiology of thrombocytopenia in chronic liver disease
by: Mitchell O, et al.
Published: (2016-04-01)

Efficacy and Safety of Avatrombopag in Patients With Thrombocytopenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Chunlu Li, et al.
Published: (2019-07-01)

Correction of Thrombocytopenia with Thrombopoietin Receptor Agonists in Patients with Liver Cirrhosis Before Elective Surgery or Invasive Procedures
by: T. A. Deeva, et al.
Published: (2025-02-01)

The thrombopoietin receptor: revisiting the master regulator of platelet production
by: Ian S. Hitchcock, et al.
Published: (2021-08-01)

Efficacy and Safety of Recombinant Human Thrombopoietin on Sepsis Patients With Thrombocytopenia: A Systematic Review and Meta-Analysis
by: Jin Zhang, et al.
Published: (2020-06-01)

Severe, Refractory Immune Thrombocytopenia Occurring After SARS-CoV-2 Vaccine
by: Helms JM, et al.
Published: (2021-04-01)

Novel Therapies to Address Unmet Needs in ITP
by: María Eva Mingot-Castellano, et al.
Published: (2022-06-01)

GPIbα is the driving force of hepatic thrombopoietin generation
by: Danielle Karakas, et al.
Published: (2021-05-01)

Single or multiple treatments with lusutrombopag in subjects with thrombocytopenia and chronic liver disease needing an invasive procedure
by: Davide Scalabrini, et al.
Published: (2023-08-01)

Factors Associated with Significant Platelet Count Improvement in Thrombocytopenic Chronic Hepatitis C Patients Receiving Direct-Acting Antivirals
by: Yen-Chun Chen, et al.
Published: (2022-02-01)

Management of Adult Patients with Immune Thrombocytopenia (ITP): A Review on Current Guidance and Experience from Clinical Practice
by: Song F, et al.
Published: (2021-07-01)

Administration of recombinant human thrombopoietin is associated with alleviated thrombocytopenia in adult intensive care unit patients with pneumonia: A single-center retrospective study
by: Bailiang Chen, et al.
Published: (2022-10-01)

Study of thrombopoietin levels in some Egyptian patients with chronic liver diseases secondary to the hepatitis C virus
by: Enayat O. Ezzat, et al.
Published: (2012-01-01)

Corticosteroid overuse in adults with immune thrombocytopenia: Cause for concern
by: Adam Cuker, et al.
Published: (2021-08-01)

Danazol one Month Treatment of Thrombocytopenia in Chronic Hepatitis C
by: Hosam Dawod, et al.
Published: (2016-03-01)

Developmental differences between newborn and adult mice in response to romiplostim
by: Katherine A. Sparger, et al.
Published: (2018-05-01)

ACVIM consensus statement on the diagnosis of immune thrombocytopenia in dogs and cats
by: Dana N. LeVine, et al.
Published: (2024-07-01)

Clinical efficacy of recombinant human thrombopoietin combined with glucocorticoids in the treatment of immune thrombocytopenia
by: Jing-xin Zhou, et al.
Published: (2022-12-01)

THE IMPACT OF HUMAN PLATELET ANTIGEN ALLELE ON ANTIPLATELET ANTIBODIES AND CRYOGLOBULINS IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA AND HEPATITIS C VIRUS-ASSOCIATED IMMUNE THROMBOCYTOPENIA
by: Cih-En Huang, et al.
Published: (2023-04-01)

Diagnostics of thrombocytopenias
by: A V Mazurov, et al.
Published: (2018-07-01)

Investigating the Role of Anti-TPO Antibodies in HIV-Associated Thrombocytopenia before and after Initiation of HAART: A Case-Control Longitudinal Study
by: Aristotelis Tsiakalos, et al.
Published: (2023-11-01)

Recent advances in the mechanisms and treatment of immune thrombocytopenia
by: Drew Provan, et al.
Published: (2022-02-01)

Use of a thrombopoietin receptor agonist in von Willebrand disease type 2B (p.V1316M) with severe thrombocytopenia and intracranial hemorrhage
by: O. Espitia, et al.
Published: (2017-07-01)

Efficacy and safety evaluation of avatrombopag in immune thrombocytopenia: analyses of a phase III study and long-term extension
by: Hanny Al‐Samkari, et al.
Published: (2022-02-01)